Academic
Publications
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers,10.1093/jnci/djn313,Journal of The National Cancer Institute,A. Eisen,J. Lubi

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers   (Citations: 23)
BibTex | RIS | RefWorks Download
A. Eisen, J. Lubinski, J. Gronwald, P. Moller, H. T. Lynch, J. Klijn, C. Kim-Sing, S. L. Neuhausen, L. Gilbert, P. Ghadirian, S. Manoukian, G. Rennerthttp://academic.research.microsoft.com/io.ashx?type=5&id=30627262&selfId1=0&selfId2=0&maxNumber=12&query=
Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.
Journal: Journal of The National Cancer Institute - J NAT CANCER INST , vol. 100, no. 19, pp. 1361-1367, 2008
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...Among those women who had a RRSO, the odds ratio (OR) of subsequent breast cancer diagnosis in those who took HRT compared to those who did not take it was 0.48 (95%CI 0.19, 1.21).[60] Thus, these studies demonstrate that HRT does not appear to abrogate the decrease in breast cancer in BRCA1 and BRCA2 carriers following RRSO.[59, 60] However, because these studies are observational and not randomized, they do need to be interpreted with ...
    • ...Among those women who had a RRSO, the odds ratio (OR) of subsequent breast cancer diagnosis in those who took HRT compared to those who did not take it was 0.48 (95%CI 0.19, 1.21).[60] Thus, these studies demonstrate that HRT does not appear to abrogate the decrease in breast cancer in BRCA1 and BRCA2 carriers following RRSO.[59, 60] However, because these studies are observational and not randomized, they do need to be interpreted with ...

    Amy S. Clarket al. Clinical Management of Hereditary Breast Cancer Syndromes

    • ... In a case-control study, Eisen et al...

    Steven A. Narod. Hormone replacement therapy and the risk of breast cancer

    • ...While there is some evidence that short-term use of hormone replacement therapy after RRSO does not negate the reduction in breast cancer risk conferred by RRSO [6, 7] careful consideration of the timing and risks versus benefits of RRSO need to be considered prior to surgery in women with BRCA1/2 mutations who are deciding on their options for cancer...

    Susan M. Domcheket al. Occult ovarian cancers identified at risk-reducing salpingo-oophorecto...

    • ... Two studies reported that hormone replacement therapy did not increase the subsequent risk of breast cancer in BRCA mutation carriers...

    Steven A. Narod. BRCA mutations in the management of breast cancer: the state of the ar...

    • ...Studies showed that approximately 3% of invasive breast cancers can be attributed to a mutation in BRCA1 or BRCA2 and women who carry a BRCA1 mutation face a lifetime risk of breast cancer of 60–80% [16]...

    Zhanwei Wanget al. A polymorphism in Werner syndrome gene is associated with breast cance...

Sort by: